Middle East Asthma Monitoring Device Market: Current Analysis and Forecast (2023-2030)

The Middle East asthma monitoring device market is a growing market that includes a range of devices used to measure and track asthma symptoms. These devices include peak flow meters, spirometers, and peak flow meters with spirometry. The market is driven by an aging population, an increase in asthma prevalence, and advances in technology. Opportunities for growth in the market include the development of new and improved devices and the increasing adoption of remote monitoring technology. Key trends in the market include the integration of asthma monitoring devices with mobile health apps and the growing use of spirometry in clinical settings.

The Middle East asthma monitoring device market was valued 56.4 million and is expected to grow at a steady rate of around 5.8% owing to growing awareness about asthma management, favorable reimbursement policies, and rising healthcare expenditure. Furthermore, technological advancements in spirometry, such as the integration of wireless connectivity and cloud-based data management, enhance patient convenience and enable remote monitoring, which will fuel the growth of the market.

Based on device, the market is segmented into spirometer, peak flow meter, and smart inhalers. The smart inhalers category is to witness higher CAGR during the forecast period owing to the increasing focus on patient-centric care, the need for improved medication adherence, and the rising adoption of digital health solutions. The integration of smart inhalers with telehealth platforms and electronic health records further enhances their market potential.

Based on end-user, the asthma monitoring device market has been classified into hospitals & clinics, homecare, and diagnostic laboratories. The homecare category is to witness higher adoption of the asthma monitoring device market during the forecast period. This is mainly due to the increasing emphasis on patient-centered care, the desire for convenience, and the need to reduce healthcare costs by avoiding unnecessary hospital visits. Asthma monitoring devices that are user-friendly, technologically advanced, and capable of remote data transmission align with the requirements of home care settings, thereby driving market growth. For instance, in 2023, koneksa, a healthcare technology company developing evidence-based validated digital biomarkers, announced the launch of a clinical study comparing the treatment effect between at-home mobile spirometry using digital biomarkers and in-clinic spirometry in patients with moderate asthma on long-acting beta-agonist (LABA) treatment.

For a better understanding of the market adoption of the Middle East asthma monitoring device industry, the market is analyzed based on its presence in the countries such as Middle East (UAE, Saudi Arabia, Qatar, Kuwait, Bahrain, Rest of the Middle East). Asthma is a significant health concern in the Middle East, with various factors contributing to its high prevalence, including environmental factors, genetics, and lifestyle changes. This has led to a demand for effective monitoring and management tools. Also, the asthma monitoring device market has been experiencing growth due to increased awareness about asthma management, rising healthcare expenditure, and advancements in technology. These devices help patients and healthcare professionals monitor symptoms, track medication usage, and adjust treatment plans accordingly. Various international and regional medical device companies are active in the Middle East asthma monitoring device market. These companies offer a variety of products designed to help individuals manage their asthma more effectively. For instance, Philips offers a range of respiratory care products, including asthma monitoring devices such as peak flow meters and spirometers. These devices help individuals monitor their lung function and manage their asthma symptoms.

Some of the major players operating in the market include: COSMED srl; Teleflex Incorporated; SCHILLER; Hill-Rom, Inc.; Koninklijke Philips N.V.; ICU Medical, Inc; SDI Diagnostics; AstraZeneca; Merck & Co., Inc.; BD.